相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
B. Eliasson et al.
DIABETOLOGIA (2012)
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Nancy J. Brown
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
William B. White et al.
AMERICAN HEART JOURNAL (2011)
Cardiovascular Effects of Glucagonlike peptide-1 Agonists
Michael H. Davidson
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis
B. R. Peskin et al.
DIABETES OBESITY & METABOLISM (2011)
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2011)
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus
Somsuvra B. Ghatak et al.
CURRENT DIABETES REVIEWS (2010)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Assessing the cardiovascular safety of diabetes therapies
Allison B. Goldfine
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Epidemiology of cardiovascular complications in type 2 diabetes mellitus
JB Meigs
ACTA DIABETOLOGICA (2003)
分享论文
